Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by Chritterson Aug 26, 2021 9:47am
124 Views
Post# 33766697

RE:Phase I first injection with R-107

RE:Phase I first injection with R-107Real News Releases is what is needed to move this needle, Most people have left or do not want to join your Group so news isnt getting out, If news doesnt get out, No one will invest, Anyone new will think nothing is happening here so they wont buy!! Easy Peasy.



Amazigh wrote: Well it seems CMAX is still operating as an essential business and is at this
moment recruiting volunteers for our Phase I study.

In the interview with Salzman about Phase I, he said:

"They come back in the night before the study begins, they stay in house, they sleep there and then, in the morning of the drug is given - early in the morning and their tested throughout the day and in the evening and then typically they will go home the next morning.  And then seven days later, they  come back for additional blood tests, urine tests as well as another medical history and physical examination and EKG."

Here is the link to the interview: https://claritasinvestors.com/index.php?/articles.html/interviews/interview-dr-salzman-7-may-2021-r123/

So, the volunteers have to be healthy, stay there two nights, and come back 7 days later for examination.
If you look through the current trials at CMAX you'll find the trial CM2620 that fits with the criteria Salzman was describing.

So, that means currently volunteers are recruited and on the 16th (a Thursday) the first injections will be given to participants of our trial (https://www.cmax.com.au/current-trial/cm2620/).

For more information and discussion you can visit clarita.ca

PS. By the way, there were people who did not believe the interviews were genuine. Well then this fact Salzman describing the process of phase I at CMAX accurately tells otherwise. Don't you think, LOL. One could argue maybe all the information given by claritasinvestors is real contrary to what some bashers and whiners believe.



<< Previous
Bullboard Posts
Next >>